Drug Development

Blog Post

FDA Accepts Sarepta Therapeutics’ New Drug Application for DMD Treatment Casimersen

By Sujatha Gurunathan | August 26, 2020
Featured Article

The Expanding Therapeutic Landscape for Myasthenia Gravis

By MDA Staff | August 14, 2020
Blog Post

FDA Approves Genentech’s Evrysdi for Treatment of SMA in Pediatric and Adult Patients

By MDA Staff | August 7, 2020
Blog Post

Biogen Announces Positive Results from Phase 1/2 Study of Tofersen to Treat a Genetic Form of ALS

By Sujatha Gurunathan | July 14, 2020
Blog Post

How MDA is Supporting LGMD Research and Care in 2020

By MDA Staff | July 10, 2020
Blog Post

Sarepta Therapeutics Announces Positive Results from the SRP-9001 Gene Therapy Trial to Treat DMD

By Sujatha Gurunathan | June 22, 2020
Blog Post

Momenta Pharmaceuticals Announces Positive Results from Phase 2 Vivacity-MG Study of Nipocalimab for Treatment of Generalized Myasthenia Gravis

By Sujatha Gurunathan | June 18, 2020
Blog Post

NS Pharma Announces Positive Results from Phase 2 Study of Viltolarsen in DMD

By Sujatha Gurunathan | June 3, 2020
Blog Post

Pfizer Announces Positive Results from Phase 1b Study of PF-06939926 for Treatment of DMD

By Sujatha Gurunathan | June 1, 2020
Blog Post

Orphazyme Announces FDA Fast Track Designation for Development of Arimoclomol for Treatment of ALS

By Sujatha Gurunathan | May 26, 2020